4d pharma analyst ratings
4d pharma analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/27/2022 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 05/13/2021 | 2021.21% | Ladenburg Thalmann | → $35 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 06/27/2022 | — | 查丹资本 | 降级 | 买入 → 中性 | |
| 2021 年 5 月 13 日 | 2021.21% | 拉登堡塔尔曼 | → 35 美元 | 启动覆盖范围开启 | → 购买 |
4d pharma Questions & Answers
4D 制药问题与解答
The latest price target for 4d pharma (NASDAQ: LBPS) was reported by Chardan Capital on June 27, 2022. The analyst firm set a price target for $0.00 expecting LBPS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
查丹资本于2022年6月27日公布了4d制药（纳斯达克股票代码：LBPS）的最新目标股价。该分析公司将目标股价定为0.00美元，预计LBPS将在12个月内降至12个月内（可能下跌-100.00％）。1家分析公司去年公布了评级。
The latest analyst rating for 4d pharma (NASDAQ: LBPS) was provided by Chardan Capital, and 4d pharma downgraded their neutral rating.
Chardan Capital对4d Pharma（纳斯达克股票代码：LBPS）的最新分析师评级由Chardan Capital提供，4d Pharma下调了中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4d pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4d pharma was filed on June 27, 2022 so you should expect the next rating to be made available sometime around June 27, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与4d制药公司的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。4d 制药的最新评级是在2022年6月27日公布的，因此您应该预计下一个评级将在2023年6月27日左右公布。
While ratings are subjective and will change, the latest 4d pharma (LBPS) rating was a downgraded with a price target of $0.00 to $0.00. The current price 4d pharma (LBPS) is trading at is $1.65, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的4d制药（LBPS）评级已下调，目标股价为0.00美元至0.00美元。目前4d Pharma（LBPS）的交易价格为1.65美元，超出了分析师的预期区间。